Forgot your username or password?
Recover it here
Not a member yet?
Register
Agoracom
The Small Cap Epicenter
The Small Cap Epicenter
AGORACOM WIRE - FRIDAY MAY 25TH, 2012
FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.
Read More | *SPONSOR
INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More
AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More
LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013 Read More | *SPONSOR
Dr. Moro-Vidal is the CEO, President, and founder of BioCurex. Previously, he developed a new diagnostic system (conductivity ELISA) and a microchip used by the National Aeronautics and Space Administration (NASA) in space. Dr. Moro-Vidal also discovered the RECAF (tm) cancer marker, the core of BioCurex's technology. He has been an officer and director of BioCurex since March 2001. Since 1996, Dr. Moro-Vidal has also been president of Pacific BioSciences Research Centre, where he developed the RECAF cancer marker concept. From 1980 to 1985, he worked in cancer research at the French National Cancer Institute near Paris, France. From late 1985 to 1988, he worked at the University of Alberta, Edmonton on oncodevelopmental biology. From 1989 to 1996, Dr. Moro-Vidal was engaged in various entrepreneurial ventures relating to diagnostics and instrumentation.
Dr. Gold has been a director of BioCurex since March 2001. He attended McGill University, where he obtained four degrees, including a Ph.D. His thesis, "Carcinoembryonic Antigens (CEAs) of the Human Digestive System," and his description of AFP are credited with ushering in the modern era of human tumor marker research, along with the diagnostic ramifications that this work has had over the past quarter century. The CEA assay, developed by Dr. Gold, has become one of the most used markers for human cancer diagnosis and monitoring. More recently, in experimental attempts to eradicate tumors with monocional antibodies (MAbs), anti-CEA antibody has been used as a homing device for cancer cell cytotoxic agents. In recognition of his scientific contributions, Dr. Gold has received numerous international awards and honors. He is currently the physician-in-chief, Department of Medicine, at the Montreal General Hospital, the Douglas G. Cameron professor of medicine at McGill Univeristy, a professor in the Departments of Physiology and Oncology at McGill Univeristy, and the director of the McGill University Medical Clinic at Montreal General Hospital.
Like BioCurex? Then you might also be interested in Star Navigation Systems Group Ltd.
